Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report report published on Monday. The brokerage issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $10.00 target price on shares of Arcadia Biosciences in a report on Friday, April 5th.

Arcadia Biosciences Trading Down 2.2 %

Shares of NASDAQ RKDA opened at $2.04 on Monday. The firm’s 50-day moving average price is $2.35 and its 200-day moving average price is $2.72. Arcadia Biosciences has a 1-year low of $1.85 and a 1-year high of $7.30.

Arcadia Biosciences (NASDAQ:RKDA) last issued its earnings results on Thursday, March 28th. The basic materials company reported ($2.48) EPS for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.20. The business had revenue of $1.17 million during the quarter, compared to analyst estimates of $1.80 million. Arcadia Biosciences had a negative return on equity of 81.56% and a negative net margin of 246.80%. On average, analysts predict that Arcadia Biosciences will post -5.01 earnings per share for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.